D&D Pharmatech Inc. (KOSDAQ:347850)

D&D Pharmatech Statistics

Total Valuation

D&D Pharmatech has a market cap or net worth of KRW 1.80 trillion. The enterprise value is 1.76 trillion.

Market Cap	1.80T
Enterprise Value	1.76T

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

D&D Pharmatech has 10.82 million shares outstanding. The number of shares has increased by 11.55% in one year.

Current Share Class	10.82M
Shares Outstanding	10.82M
Shares Change (YoY)	+11.55%
Shares Change (QoQ)	+1.35%
Owned by Insiders (%)	20.71%
Owned by Institutions (%)	16.70%
Float	8.06M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	192.34
PB Ratio	22.92
P/TBV Ratio	37.07
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-47.48
EV / Sales	188.75
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-65.38

Financial Position

The company has a current ratio of 8.70, with a Debt / Equity ratio of 0.09.

Current Ratio	8.70
Quick Ratio	7.66
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.26
Interest Coverage	-52.38

Financial Efficiency

Return on equity (ROE) is -46.88% and return on invested capital (ROIC) is -22.01%.

Return on Equity (ROE)	-46.88%
Return on Assets (ROA)	-18.79%
Return on Invested Capital (ROIC)	-22.01%
Return on Capital Employed (ROCE)	-33.73%
Revenue Per Employee	444.44M
Profits Per Employee	-1.77B
Employee Count	21
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	-899.13M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +360.83% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+360.83%
50-Day Moving Average	144,474.00
200-Day Moving Average	86,976.00
Relative Strength Index (RSI)	62.60
Average Volume (20 Days)	630,733

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, D&D Pharmatech had revenue of KRW 9.33 billion and -37.11 billion in losses. Loss per share was -3,495.95.

Revenue	9.33B
Gross Profit	9.31B
Operating Income	-31.22B
Pretax Income	-38.95B
Net Income	-37.11B
EBITDA	-25.61B
EBIT	-31.22B
Loss Per Share	-3,495.95

Balance Sheet

The company has 40.00 billion in cash and 6.90 billion in debt, giving a net cash position of 33.10 billion or 3,058.59 per share.

Cash & Cash Equivalents	40.00B
Total Debt	6.90B
Net Cash	33.10B
Net Cash Per Share	3,058.59
Equity (Book Value)	78.33B
Book Value Per Share	7,278.27
Working Capital	43.31B

Cash Flow

In the last 12 months, operating cash flow was -26.56 billion and capital expenditures -381.31 million, giving a free cash flow of -26.94 billion.

Operating Cash Flow	-26.56B
Capital Expenditures	-381.31M
Free Cash Flow	-26.94B
FCF Per Share	-2,489.91

Margins

Gross Margin	99.72%
Operating Margin	-334.52%
Pretax Margin	-417.34%
Profit Margin	n/a
EBITDA Margin	-274.35%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

D&D Pharmatech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.55%
Shareholder Yield	n/a
Earnings Yield	-2.07%
FCF Yield	-1.50%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

D&D Pharmatech has an Altman Z-Score of 11.86 and a Piotroski F-Score of 2.

Altman Z-Score	11.86
Piotroski F-Score	2